Participant consumed grapefruit or grapefruit solutions within 3 days just before the first dose of study drug. - Participant eaten grapefruit or grapefruit products within three times before the first dose of study drug. In Section C, individuals will receive ABBV-744 and oral navitoclax. In Phase D, contributors will get https://abbv-744clinicaltrialphas65802.dreamyblogs.com/32437553/abbv-744-cancer-treatment-clinical-trials-an-overview